{"product_id":"complete-conference-management-30th-annual-heart-failure-2026","title":"Complete Conference Management 30th Annual Heart Failure 2026","description":"\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eComplete Conference Management 30th Annual Heart Failure 2026\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cem\u003eAdvanced Heart Failure, Cardiomyopathy \u0026amp; Contemporary Cardiovascular Therapy Update\u003c\/em\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe Complete Conference Management 30th Annual Heart Failure 2026 program provides a comprehensive review of contemporary heart failure management, focusing on the latest advances in prevention, diagnosis, pharmacologic therapy, device-based interventions, and long-term patient care.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eCelebrating its 30th year, this highly regarded symposium brings together leading cardiovascular experts to discuss evidence-based strategies for managing acute and chronic heart failure across a broad spectrum of clinical presentations. The program emphasizes practical clinical decision-making, guideline-directed medical therapy (GDMT), emerging treatment options, and multidisciplinary approaches designed to improve patient outcomes.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThrough expert-led lectures, clinical updates, and interactive discussions, participants gain valuable insight into current and future approaches to heart failure management, including cardiomyopathies, valvular heart disease, pulmonary hypertension, cardiorenal syndromes, and advanced heart failure therapies.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eCourse Features\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• 8 Video Lectures\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• 8 VTT Subtitle Files\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• 29 PDF Presentations\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Total Size: 5.99 GB\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Expert Faculty Presentations\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Evidence-Based Clinical Updates\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Interactive Panel Discussions\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Hybrid Conference Format\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Advanced Heart Failure Education\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eTarget Audience\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThis course is ideal for:\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Cardiologists\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Advanced Heart Failure Specialists\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Internists\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Primary Care Physicians\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Intensivists\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Pharmacists\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Nurse Practitioners\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Nurses\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Healthcare Professionals Involved in Cardiovascular Care\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eIt is particularly valuable for clinicians seeking:\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Guideline-Directed Medical Therapy (GDMT) Updates\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Advanced Heart Failure Management\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Cardiogenic Shock Education\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Cardiomyopathy Treatment Strategies\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Heart Failure Pharmacotherapy Updates\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Valvular Heart Disease Interventions\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Cardiorenal Syndrome Management\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Contemporary Cardiovascular Guidelines\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eProgram Overview\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eHeart failure remains one of the leading causes of cardiovascular morbidity and mortality worldwide. Rapid advances in pharmacologic therapies, device-based treatments, imaging technologies, and precision medicine continue to transform patient care and improve outcomes.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe 30th Annual Heart Failure 2026 symposium provides an extensive review of contemporary approaches to managing patients with heart failure across all stages of disease. The curriculum explores current evidence, emerging therapies, updated guidelines, and challenging clinical scenarios frequently encountered in cardiovascular practice.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eSpecial emphasis is placed on the prevention and treatment of heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), acute decompensated heart failure, cardiogenic shock, and complex cardiomyopathies.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eParticipants will leave with practical recommendations and evidence-based strategies that can be immediately applied to improve the care of patients with heart failure and related cardiovascular conditions.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eLearning Objectives\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eUpon completion of this activity, participants will be able to:\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Review current hypertension and lipid management guidelines relevant to cardiovascular risk reduction\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Apply contemporary treatment strategies for HFrEF and HFpEF\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Integrate evidence-based pharmacologic therapies into heart failure management\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Manage patients with acute decompensated heart failure\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Evaluate and treat heart failure patients with concurrent kidney disease\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Discuss optimal management of atrial fibrillation in heart failure patients\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Understand catheter-based interventions for valvular heart disease\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Develop treatment strategies for hypertrophic cardiomyopathy and cardiac amyloidosis\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Address obesity-related challenges in heart failure management\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Apply current approaches to pulmonary arterial hypertension\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eCore Topics Covered\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eGuideline-Directed Medical Therapy (GDMT)\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Contemporary Heart Failure Guidelines\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• HFrEF Management\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• HFpEF Management\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Pharmacologic Optimization\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Evidence-Based Treatment Algorithms\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eAdvanced Heart Failure Management\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Acute Decompensated Heart Failure\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Advanced Heart Failure Therapies\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Cardiogenic Shock\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Mechanical Circulatory Support\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Referral Strategies for Advanced Care\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eCardiomyopathies \u0026amp; Infiltrative Heart Disease\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Hypertrophic Cardiomyopathy\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Cardiac Amyloidosis\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Genetic Testing \u0026amp; Precision Medicine\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Inherited Cardiovascular Disorders\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eHeart Failure \u0026amp; Kidney Disease\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Cardiorenal Syndrome\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Renal Protection Strategies\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Integrated Heart-Kidney Management\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Therapeutic Decision-Making\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eArrhythmias in Heart Failure\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Atrial Fibrillation Management\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Rhythm Control Strategies\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Anticoagulation Considerations\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Device-Based Therapies\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eValvular Heart Disease\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Catheter-Based Valve Interventions\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Structural Heart Disease\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Patient Selection Strategies\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Procedural Advances\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003ePulmonary Hypertension\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Pulmonary Arterial Hypertension\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Right Heart Failure\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Diagnostic Evaluation\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Contemporary Treatment Approaches\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eSpecial Populations\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Obesity \u0026amp; Heart Failure\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Peripartum Cardiomyopathy\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Myocarditis\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Geriatric Heart Failure Care\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003ePrevention \u0026amp; Risk Reduction\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Hypertension Management\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Hyperlipidemia Treatment\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Cardiovascular Prevention Strategies\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e• Early Detection of Heart Failure\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eEducational Features\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Expert-Led Cardiovascular Education\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Comprehensive Heart Failure Updates\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Evidence-Based Clinical Recommendations\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Advanced Cardiomyopathy Management\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Interactive Faculty Discussions\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Contemporary Guideline Reviews\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Practical Clinical Applications\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Immediate Relevance to Daily Practice\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eWhy This Course Stands Out\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Celebrating 30 Years of Excellence in Heart Failure Education\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Comprehensive Coverage of Acute \u0026amp; Chronic Heart Failure\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Strong Focus on Guideline-Directed Medical Therapy\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Expert Insights into Complex Cardiovascular Cases\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Advanced Cardiomyopathy \u0026amp; Amyloidosis Education\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Contemporary Device \u0026amp; Structural Heart Updates\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Practical Management Strategies for Real-World Patients\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e✔ Multidisciplinary Approach to Cardiovascular Care\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003eClinical \u0026amp; Educational Value\u003c\/strong\u003e\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe Complete Conference Management 30th Annual Heart Failure 2026 program delivers an in-depth review of modern heart failure care, combining current guidelines, emerging therapies, advanced diagnostics, and practical management strategies.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eBy integrating updates in pharmacotherapy, device therapy, cardiomyopathy management, structural heart disease, pulmonary hypertension, and cardiovascular prevention, this course equips clinicians with the knowledge necessary to optimize outcomes for patients with heart failure across diverse clinical settings.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe program is an outstanding educational resource for cardiologists, internists, primary care physicians, and advanced heart failure specialists seeking the latest evidence-based approaches to cardiovascular care.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n \r\n\u003ch2 data-path-to-node=\"6\"\u003e4. Topics\u003c\/h2\u003e\r\n\u003cp data-path-to-node=\"7\"\u003e*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below\u003c\/p\u003e\r\n\r\n\u003col start=\"1\" data-path-to-node=\"8\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,0,0\"\u003eCase Discussions\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,1,0\"\u003eProduct Theatre Breakfast – Non-CME Navigating Fabry Disease\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,2,0\"\u003eSESSION I\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,3,0\"\u003eSESSION II\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,4,0\"\u003eSESSION III\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,5,0\"\u003eSESSION IV\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,6,0\"\u003eSESSION V\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"8,7,0\"\u003eSESSION VI\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n* Detail:\r\n\u003cdiv class=\"w3-container\"\u003e\r\n\r\n\u003cstrong\u003eFRIDAY, March 13, 2026\u003c\/strong\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"w3-row\"\u003e\r\n\u003cdiv class=\"w3-col w3-container w3-teal\"\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e11:00am-12:00pm \u003cstrong\u003eRegistration, Coffee, Visit Exhibits\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e12:00-1:00pm \u003cstrong\u003eProduct Theatre Luncheon\u003c\/strong\u003e – \u003cem\u003eNon-CME \u003c\/em\u003e\u003cstrong\u003eEvidence – Based Treatment of Recurrent Pericarditis \u003c\/strong\u003eMariko Harper, MD, MS, FACC \u003cem\u003eSupported by:\u003c\/em\u003e \u003cstrong\u003eKiniksa\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e1:00-1:15pm \u003cem\u003eCoffee Break and Visit Exhibits\u003c\/em\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eSESSION I\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e1:15-1:25pm \u003cstrong\u003eIntroduction to the 30th Annual Symposium: Heart Failure 2026 – An Update on Therapy \u003c\/strong\u003eUri Elkayam, MD, FACC\u003c\/li\u003e\r\n \t\u003cli\u003e1:25-1:45pm \u003cstrong\u003eManagement of the Hospitalized Patients with Decompensated Heart Failure \u003c\/strong\u003eUri Elkayam, MD, FACC\u003c\/li\u003e\r\n \t\u003cli\u003e1:45-2:05pm \u003cstrong\u003eBalancing GDMT and Hyperkalemia \u003c\/strong\u003eIleana L. Piña, MD\u003c\/li\u003e\r\n \t\u003cli\u003e2:05-2:25pm \u003cstrong\u003eDigitoxin in Heart Failure: A Comeback for Digitalis? \u003c\/strong\u003eTien Ng, PharmD\u003c\/li\u003e\r\n \t\u003cli\u003e2:25-2:45pm \u003cstrong\u003eIntroducing Finerenone: A New Drug for the Management of Heart Failure and Chronic Kidney Disease \u003c\/strong\u003eAkshay Desai, MD\u003c\/li\u003e\r\n \t\u003cli\u003e2:45-3:05pm \u003cstrong\u003eVericiguat in Heart Failure: When and How to Use It \u003c\/strong\u003eBarry Greenberg, MD\u003c\/li\u003e\r\n \t\u003cli\u003e3:05-3:25pm \u003cstrong\u003eThe Contemporary Management of HFpEF \u003c\/strong\u003eAkshay Desai, MD\u003c\/li\u003e\r\n \t\u003cli\u003e3:25-3:40pm \u003cem\u003eCoffee Break and Visit Exhibits\u003c\/em\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eSESSION II\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e3:40-4:00pm \u003cstrong\u003eOur Journey with Diuretics: 240 Years, and How Far Have We Come? \u003c\/strong\u003eMarvin Konstam, MD\u003c\/li\u003e\r\n \t\u003cli\u003e4:00-4:20pm \u003cstrong\u003eTreating Congestion in Patients with Acute Decompensated Heart Failure: Where Are We Now? Where Are We Going? \u003c\/strong\u003eWilliam Abraham, MD\u003c\/li\u003e\r\n \t\u003cli\u003e4:20-4:40pm \u003cstrong\u003eReleasing the Brakes on the Immune System in Cancer: Implications in Myocarditis and Beyond \u003c\/strong\u003eEric Yang, MD\u003c\/li\u003e\r\n \t\u003cli\u003e4:40-5:00pm \u003cstrong\u003eClinical Experience with the Use of Myosin Inhibitors in the Treatment of Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy \u003c\/strong\u003eJessica Wang, MD\u003c\/li\u003e\r\n \t\u003cli\u003e5:00-5:20pm \u003cstrong\u003eContemporary Management of Obesity in Patients with Heart Failure \u003c\/strong\u003eNorman Lepor, MD\u003c\/li\u003e\r\n \t\u003cli\u003e5:20pm \u003cstrong\u003eAdjourn\u003c\/strong\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eSATURDAY, March 14, 2026\u003c\/strong\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e\r\n\u003cdiv class=\"w3-row\"\u003e\r\n\u003cdiv class=\"w3-col w3-container w3-teal\"\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e7:00am \u003cstrong\u003eRegistration Open\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e7:15-7:45am \u003cstrong\u003eCase Discussion \u003c\/strong\u003eUri Elkayam, MD and Barry Greenberg, MD\u003c\/li\u003e\r\n \t\u003cli\u003e7:45-8:45am \u003cstrong\u003eProduct Theatre Breakfast\u003c\/strong\u003e – \u003cem\u003eNon-CME \u003c\/em\u003e\u003cstrong\u003eNavigating Fabry Disease \u003c\/strong\u003eDr. Anjay Rastogi \u003cem\u003eSupported by:\u003c\/em\u003e \u003cstrong\u003eSanofi\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e8:45-9:00am \u003cem\u003eBreak and Visit the Exhibits\u003c\/em\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eSESSION III\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e9:00-9:15am \u003cstrong\u003eIntroduction to Day Two: 30th Annual Symposium: Heart Failure 2026 – An Update on Therapy \u003c\/strong\u003eUri Elkayam, MD\u003c\/li\u003e\r\n \t\u003cli\u003e9:15-9:35am \u003cstrong\u003eGDMT for Chronic HFrEF: How to Maximize the Benefits? \u003c\/strong\u003eGregg Fonarow, MD\u003c\/li\u003e\r\n \t\u003cli\u003e9:35-9:55am \u003cstrong\u003eCardiogenic Shock: Hemodynamic Classification and Management \u003c\/strong\u003eRola Khedraki, MD\u003c\/li\u003e\r\n \t\u003cli\u003e9:55-10:15am \u003cstrong\u003ePercutaneous Coronary Interventions in Ischemic Cardiomyopathy – Does It Work? \u003c\/strong\u003eChristina Economides, MD\u003c\/li\u003e\r\n \t\u003cli\u003e10:15-10:35am \u003cstrong\u003eBio-Omics in Heart Failure Diagnosis and Therapy \u003c\/strong\u003eKirkwood Adams, MD\u003c\/li\u003e\r\n \t\u003cli\u003e10:35-10:55am \u003cem\u003eBreak and Visit the Exhibits\u003c\/em\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eSESSION IV\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e10:55-11:15am \u003cstrong\u003eGenetic Testing for Cardiomyopathy \u003c\/strong\u003eJosh Hare, MD\u003c\/li\u003e\r\n \t\u003cli\u003e11:15-11:35am \u003cstrong\u003eGene Therapy for Patients with Cardiomyopathy \u003c\/strong\u003eBarry Greenberg, MD\u003c\/li\u003e\r\n \t\u003cli\u003e11:35-11:55am \u003cstrong\u003eStem Cell Therapy for the Management of Myocardial Disease: A Status Report \u003c\/strong\u003eJosh Hare, MD\u003c\/li\u003e\r\n \t\u003cli\u003e11:55-12:15pm \u003cstrong\u003eClinical Characteristics and Management of Methamphetamine-Associated Cardiomyopathy \u003c\/strong\u003eUri Elkayam, MD\u003c\/li\u003e\r\n \t\u003cli\u003e12:15-12:35pm \u003cstrong\u003eUpdate on the Management of Atrial Fibrillation in Patients with Heart Failure \u003c\/strong\u003eAnil Bhandari, MD\u003c\/li\u003e\r\n \t\u003cli\u003e12:35-1:35pm \u003cstrong\u003eProduct Theatre Luncheon\u003c\/strong\u003e – \u003cem\u003eNon-CME \u003c\/em\u003e\u003cstrong\u003ePivotal Trial and Cardiac Structure and Function Outcomes With CAMZYOS® in Patients With Symptomatic NYHA Class II-III Obstructive HCM \u003c\/strong\u003eFlorian Rader, MD \u003cem\u003eSupported by:\u003c\/em\u003e \u003cstrong\u003eBristol Myers Squibb\u003c\/strong\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e1:35-1:50pm \u003cem\u003eBreak and Visit the Exhibits\u003c\/em\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eSESSION V\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e1:50-2:20pm \u003cstrong\u003eKEYNOTE LECTURE \u003c\/strong\u003e\u003cstrong\u003e30 Years of Innovation in the Management of Heart Failure: A Perspective \u003c\/strong\u003eClyde Yancy, MD\u003c\/li\u003e\r\n \t\u003cli\u003e2:20-2:40pm \u003cstrong\u003eBromocriptine in the Management of Peripartum Cardiomyopathy: Pathophysiologic Mechanism and Available Data \u003c\/strong\u003eUri Elkayam, MD\u003c\/li\u003e\r\n \t\u003cli\u003e2:40-3:00pm \u003cstrong\u003eWhat Is New in Myocarditis: An Update from the ESC 2025 Guidelines \u003c\/strong\u003eLeslie Cooper, MD\u003c\/li\u003e\r\n \t\u003cli\u003e3:00-3:20pm \u003cstrong\u003ePulmonary Hypertension: New Drugs and How to Use Them \u003c\/strong\u003eThomas Heywood, MD\u003c\/li\u003e\r\n \t\u003cli\u003e3:20-3:40pm \u003cstrong\u003eInnovations in Device Therapy for Heart Failure \u003c\/strong\u003eWilliam Abraham, MD\u003c\/li\u003e\r\n \t\u003cli\u003e3:40-4:00pm \u003cem\u003eBreak and Visit Exhibits\u003c\/em\u003e\n\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eSESSION VI\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e4:00-4:20pm \u003cstrong\u003eThe Use of AI in the Management of Heart Failure \u003c\/strong\u003eNir Uriel, MD\u003c\/li\u003e\r\n \t\u003cli\u003e4:20-4:40pm \u003cstrong\u003eAutonomic Modulation in Heart Failure Treatment: Where Are We and Where Are We Heading? \u003c\/strong\u003eMarvin Konstam, MD\u003c\/li\u003e\r\n \t\u003cli\u003e4:40-5:00pm \u003cstrong\u003eLVAD vs Heart Transplantation: A Perspective \u003c\/strong\u003eNir Uriel, MD\u003c\/li\u003e\r\n \t\u003cli\u003e5:00-5:20pm \u003cstrong\u003eIndividual Selection of Drug Therapy in Patients with Transthyretin (TTR) Amyloidosis \u003c\/strong\u003eMazen Hanna, MD\u003c\/li\u003e\r\n \t\u003cli\u003e5:20pm \u003cstrong\u003eAdjourn\u003c\/strong\u003e\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/div\u003e\r\n\u003c\/div\u003e","brand":"Medical Amboss","offers":[{"title":"Default Title","offer_id":42979217342562,"sku":"MED-AMB09210","price":30.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Complete-Conference-Management-30th-Annual-Heart-Failure-2026.jpg?v=1780327309","url":"https:\/\/meducourse.com\/products\/complete-conference-management-30th-annual-heart-failure-2026","provider":"Meducourse","version":"1.0","type":"link"}